Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has been assigned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $32.00.

Several equities research analysts have weighed in on CPRX shares. HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $35.00 to $31.50 in a report on Thursday, May 28th. Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Stephens set a $32.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Finally, Zacks Research cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $31.45 on Friday. Catalyst Pharmaceuticals has a 52-week low of $19.05 and a 52-week high of $32.56. The stock has a market cap of $3.85 billion, a P/E ratio of 18.07, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74. The business’s 50 day moving average is $30.93 and its 200 day moving average is $26.50.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several hedge funds have recently modified their holdings of the business. Parkside Financial Bank & Trust boosted its stake in shares of Catalyst Pharmaceuticals by 17.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 469 shares in the last quarter. Oregon Public Employees Retirement Fund increased its holdings in Catalyst Pharmaceuticals by 1.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock valued at $617,000 after buying an additional 472 shares during the period. PNC Financial Services Group Inc. raised its stake in Catalyst Pharmaceuticals by 4.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,554 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 474 shares in the last quarter. Lifestyle Asset Management Inc. raised its stake in Catalyst Pharmaceuticals by 3.4% in the fourth quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock worth $393,000 after buying an additional 553 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in Catalyst Pharmaceuticals by 55.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 630 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).